Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 42

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 42
---
 to us are not presently determinable and may be substantially less than the maximum amounts set forth herein. We may sell
fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in
this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations,
including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in
the short-term and may need to raise additional funds to complete such short-term operations. Such additional fundraises may not be available
or available on terms acceptable to us.

| 22 |

If you purchase our securities in either the Company Offering or the Inducement Offering you may incur immediate and substantial dilution in the book value of your shares.

The combined public offering
price per share of our common stock and accompanying warrant may be substantially higher than the net tangible book value per share of
our common stock immediately prior to the offering. After giving effect to the assumed sale of shares of our common stock and accompanying
warrants in this Company Offering, at an assumed combined public offering price of $ 2.19 per share and accompanying warrant (the
last reported sale price of our common stock on The Nasdaq Capital Market on August 21, 2025), and after deducting the placement agent
fees and estimated offering expenses payable by us and attributing no value to the warrants sold in this offering, purchasers of our
common stock in this offering will incur immediate dilution of $0.43 per share in the net tangible book value of the common stock
they acquire. In the event that you exercise your warrants, you may experience additional dilution to the extent that the exercise price
of the warrants is higher than the tangible book value per share of our common stock. For a further description of the dilution that
investors in this offering may experience, see “Dilution.”

In addition, to the extent that
outstanding stock options or warrants, including the Inducement Warrants have been or may be exercised, outstanding restricted stock units
have been or may be settled or other shares are issued, you may experience further dilution.

We have broad discretion in the use of the net proceeds we receive from the Company Offering and may not use them effectively.

Our management will have broad
discretion in the application of the net proceeds we receive in the Company Offering, including for any of the purposes described